Name: Fumarates for Treatment of RMS
Uploaded: 2021-01-26T17:00:14Z
Description: Fumarates for Treatment of RMS

Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Parkinson Gene Therapy AB-1005 Continues to Show Promising Results at 18 Months

Videos

The instructor in neurology at Brigham and Women's Hospital talked about research exploring takotsubo syndrome, a heart condition often triggered by emotional or physical stressors, and its relationship with brain lesions. [WATCH TIME: 5 minutes]

Takotsubo Syndrome and the Brain-Heart Connection: Frederic Schaper, MD, PhD

Neal K. Shah, CEO of CareYaya Health Technologies, an AI innovator in neurological care, discussed how technology is poised to transform the fight against Parkinson, with the potential to improve millions of lives and advance health equity.

The AI Revolution That Could Slow Parkinson In Its Tracks

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Ian Kremer. [LISTEN TIME: 35 minutes]

Episode 113: Lessons Learned in Alzheimer Drug Development

Chief of the Division of MS and Neuroimmunology at UConn Health.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]

Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MD

Dermatology resident, University Hospitals.

A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]

Investigating Limb Swelling in Patients With Dravet Syndrome: Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

Director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital.

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Updates in the Management of Relapsing Multiple Sclerosis

Fred Lublin, MD; Patricia K. Coyle, MD; Mark Freedman, MD; and Scott D. Newsome, DO, discuss a number of topics pertaining to the diagnosis of multiple sclerosis, including a focus on fatigue and its impact on quality of life.

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis 

Use of MRI in Diagnosing Multiple Sclerosis 

Misdiagnosis of Multiple Sclerosis

Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

Challenges in Optimally Treating Multiple Sclerosis

 QoL Issues in the Management of Multiple Sclerosis

Multiple Sclerosis Fatigue

TRIUMPHANT-MS Trial: Fatigue in MS

OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

Strategies for Choosing Initial Therapy in MS

Anti-CD20 Monoclonal Antibodies for Treatment of RMS

Cladribine for Treatment of RMS

S1P Receptor Modulators for Treatment of RMS

Fumarates for Treatment of RMS

The Future of Managing Multiple Sclerosis

Peer Exchange

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Fumarates for Treatment of RMS

EP: 1.2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

EP: 2.Use of MRI in Diagnosing Multiple Sclerosis

EP: 3.Misdiagnosis of Multiple Sclerosis

EP: 4.Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

EP: 5.Challenges in Optimally Treating Multiple Sclerosis

EP: 6. QoL Issues in the Management of Multiple Sclerosis

EP: 7.Multiple Sclerosis Fatigue

EP: 8.TRIUMPHANT-MS Trial: Fatigue in MS

EP: 9.OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

EP: 10.Strategies for Choosing Initial Therapy in MS

EP: 11.Anti-CD20 Monoclonal Antibodies for Treatment of RMS

EP: 12.Cladribine for Treatment of RMS

EP: 13.S1P Receptor Modulators for Treatment of RMS

EP: 14.Fumarates for Treatment of RMS

EP: 15.The Future of Managing Multiple Sclerosis